Niflam (Niflumic Acid)

Niflumic Acid, the active ingredient in Niflam, is a fenamate (nonsteroidal anti-inflammatory drug) presented as an oral dosage form for systemic use. It is employed to relieve pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis. GNH USA supplies Niflam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Niflam, a fenamate NSAID, acts on the cyclo‑oxygenase pathway to reduce inflammatory prostaglandins. - Pain relief: alleviates moderate to severe nociceptive pain. - Rheumatoid arthritis: decreases joint swelling and improves function. - Osteoarthritis: reduces chronic joint discomfort and stiffness. - Inflammatory conditions: controls inflammation in various soft‑tissue disorders.

Adverse reactions may occur with Niflam use.

Common Side Effects: - Gastrointestinal upset: nausea, dyspepsia, abdominal pain. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Skin rash or pruritus. - Elevated liver enzymes.

Serious or Rare Side Effects: - Severe gastrointestinal bleeding or ulceration. - Hepatotoxicity: jaundice, hepatitis. - Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Blood dyscrasias: agranulocytosis, thrombocytopenia. - Anaphylactic or severe allergic reactions.

Before prescribing Niflam, consider patient‑specific risk factors and monitor appropriately. - Renal impairment: adjust use and monitor renal function. - Hepatic disease: avoid in severe liver dysfunction. - Cardiovascular risk: use cautiously in patients with hypertension or heart disease. - Gastro‑intestinal ulcer history: assess risk of bleeding. - Concomitant anticoagulants: monitor for enhanced bleeding. - Pregnancy category unknown: avoid unless benefit outweighs risk. - Store at ambient temperature: keep below 25 °C, in original container, protected from moisture.

Niflam may interact with several drug classes; awareness helps prevent adverse events.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or aspirin: additive gastrointestinal toxicity. - Corticosteroids: heightened ulcer risk. - Lithium: elevated lithium levels. - ACE inhibitors or ARBs: possible renal function decline.

Moderate Interactions (Monitor Closely): - Antihypertensives: may reduce blood pressure effect. - Methotrexate: potential for increased toxicity. - SSRIs or SNRIs: modest increase in bleeding risk. - Diuretics: may affect renal clearance. - Oral hypoglycemics: possible alteration of glucose control.